drugset / Trial / NCT02029495

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495

Phase 3 Terminated 478 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.

Timeline

Start
2014-03
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Brodalumab Monoclonal antibody 140 mg Subcutaneous
Subject Brodalumab Monoclonal antibody 210 mg Subcutaneous

Indications